Dr. James R. Conway
Address:

Diabetes Clinic
218 Percy St.
Smiths Falls, ON
K7A 4W8

Telephone: (613) 284-0145
Fax: (613) 283-9020
Toll Free: 1-800-717-0145
Email: diabetes@igs.net

Curriculum Vitae: (updated Oct 27, 2008)

Born: 16 Feb 1945. Poole, England
Citizenship: Canadian
 
Education:
Primary: England
Secondary: Ashbury College, Ottawa
University:  University of London, England, Pre-Medical
            University of Ottawa, M.D. 1972
Post Graduate: Ottawa General Hospital   
Residency in Internal Medicine 1973 
Licensing:
LMCC 1973 No 35,294
College of Physicians & Surgeons of Ontario Lic 25809
 
Professional Liability Insurance: CMPA Reg No. 120138
No previous or outstanding history of disciplinary or malpractice actions
Professional Associations:
  • Ontario Medical Assoc
  • Canadian Medical Association
  • American Diabetes Association
  • Canadian Diabetes Association; member of the Clinical & Scientific Section, Associate Editor Canadian Diabetes
  • Canadian Society of Endocrinology & Metabolism
  • European Association for the Study of Diabetes
  • International Diabetes Federation
  • Ontario Coroners Association
  • Canadian Association of Aviation Medical Examiners 
Hospital Affiliation:
  • Perth & Smiths Falls Community Hospitals (Active Staff)
  • Sault Area Hospitals (Consultant Staff)
  • Rideau Regional Centre, Smiths Falls (Consultant Staff)
Medical Practice:
Diabetes Clinic, Referral Practice limited to Diabetes Mellitus. (See address and phone number above)
Special Interests:
  • Intensive Management of Diabetes
  • Insulin Pumps
  • Clinical Research
  • Medical Education of Family Practitioners 
  • Educational Web Site (www.diabetesclinic.ca)
Research Studies Completed:
  • Zestril (Lisinopril) Post Marketing Studies 1990
  • Diamicron (Gliclazide) Post Marketing Studies 1985
  • Diascan Study 1999, published Diabetes Care
  • AZA3002 Telmisarten in Hypertension 2000-2001
  • Avandia Outcomes Study 2000-2001
  • Rosiglitazone in Family Practice 2000-2001
  • Wyeth-Ayerst PTP 112 2002 (Phase 2) Aldose Reductase
  • Aventis HOE901/3502
  • GSK-Avandia 137 (Rosiglitazone & Microalbuminuria)
  • BMS –298585
  • Astra-Zeneca POLARIS
  • COSMOS
  • Avandaryl
  • Conjuchem DM 100-102 GLP-1 (Phase 2)
  • DREAM Study 2001-2006 Diabetes Prevention with Ramipril & Rosiglitazone
  • ORIGIN Study Diabetes Prevention with Glargine
  • Pfizer Inhaled Insulin Therapy
  • CHRC-VP Registry
  • PREDICTIVE (Insulin Determir) (Phase 3) 2006
  • Astra-Zeneca G-PLUS (Tesaglitazar)
  • Novolin Pen 4 Clinical Experience (Phase 4)
  • Astra-Zeneca Gallant 8 & GALLEX (Tesaglitazar)
  • GSK-ACME
  • ACCESS (Lilly) Pioglitazone
  • SOCCER (McMaster)
  • IMPROVE (Pre-Mix Analogue Insulin) 2007
  • JUPITER (Statins & CRP, CV Outcomes) 2008
  • AEREX (Inhaled insulin) 2008
  • Sanofi-Aventis Lantu-C-00579 (Phase 3),  (Long acting insulin analogues) 2008
  • AVALANCHE Study (GSK & Canadian Heart Research Centre)
  • GSK-ADG20001 Avandia & Metformin in new onset diabetes
  • METABOLIC (Merck Frosst)
  • GSK AVT 105913 (Phase 3)
  • Astra-Zeneca RELIEF (Diabetic Neuropathy)
Current Research Studies:
    • Navigator Study 2001-2008, Diabetes Prevention, Valsarten &  Nateglinide
    • DECIDE (Pfizer)
    • GUIDE (Canadian Heart Research Centre)
    • GSK DPB 106086 (Phase 3)
    • NovoNordisk PDS316-1777 (Phase 4)
    • Merck Alpha Study (Phase 4) Sitagliptin
    • DM-200-102 (Conjuchem) Long acting GLP-1 analogue (Phase 2)
    • Pfizer Nephropathy (Phase 2) AGE-RAGE inhibition in nephropathy
    • Lilly F3Z-S020 (Phase 4) Comparison of insulin regimes
    • ADAPT Study (Statin)
    • Sanfi-Aventis EFC 6016-6019  GLP-1 Analogue in combination with other hypoglycemic agents (Phase 3)
    Publications:
    • E Coli H-157 in Nursing Home Patients: J Inf Dis 1992
    • The Case of the Exploding Cop: Diabetes Monitor 1998 (2)305
    • Rosiglitazone in Family Practice: Diabetes, June 2001, Suppl
    • Insulin Resistance in Diabetes Mellitus, Medical Post, Nov 2001, Suppl
    • Rosiglitazone in Family Practice, Cdn J Diabetes Care, meeting suppl, Oct 2001 (abstract)
    • Option or Essential Tool? Insulin Pump Therapy in Young Women: Diabetes, June 2002, Suppl
    • Guidelines, Do They Make a Difference? Canadian Journal of Diabetes. 2002;26(suppl):256.
    • Community Based Insulin Pump Program Outcomes. Canadian Journal of Diabetes. 2002;26(suppl);272.
    • Pioglitazone in Family Practice. Canadian Journal of Diabetes. 2002;26(suppl);308.
    • Rosiglitazone in Family Practice. Canadian Journal of Diabetes. 2002;26 (suppl);308
    • ,i>A Community Based Insulin Pump Program.
    • Diabetes. 2003;52 (Suppl 1) A518 Abstract 2246-PO
    • Effectiveness of Rosiglitazone in Family Practice in Canada. Diabetes & Metabolism 2003,29,4S246, Abstract 2274
    • Practical Application of Rosiglitazone in Clinical Practice. Diabetes & Metabolism 2003,29,4S246, Abstract 22772
    • 2003 CDA Clinical Practice Guidelines, are they achievable. Canadian Journal of Diabetes 2003 Sept (Abstract)
    • New Issues in the Management of Hypertension. Medical Post 2003, Suppl
    • Type 2 Diabetes, A Family Physicians Guide, 2004
    • Practical Application of Rosiglitazone in Clinical Practice. Diabetes 2004 June, Vol 53, Suppl 1 A121 (Abstract)
    • Diabetes Flow Sheet with Feedback to Improve CPG Compliance. Canadian Journal of Diabetes. 2004 Sep, Vol 28 No 3, P 314
    • Peri-Op & Peri-ACS Glucose Control. Canadian Diabetes, 18(2),Summer 2005 (Editorial)
    • Type 2 Diabetes, A Health Professional's Guide, 2006
    • Sexual Dysfunction in Diabetes. Canadian Diabetes. 19(1), Spring 2006 (Editorial)
    • A Randomized Trial of Adding Insulin Glargine vs avoidance of Insulin in People with Type 2 Diabetes on either no oral glucose lowering agents or submaximal doses of Metformin and/or Sulphonylureas. The Canadian INSIGHT Study. Diabetic Medicine. 2006;
    • Hypertension & Diabetic Retinopathy. Medical Post. 20 June 2006, Suppl
    • Aggressive Cardiovascular Treatment Needed for People with Diabetes. Canadian Diabetes Vol 19, No 3, 2006 (Editorial)
    • Necessite d'un traitment cardio-vasculaire energique en presence de diabete. Canadian Diabetes Vol 19, No 3, 2006 (Ed)
    • Advances in management options for insulin-dependent patients. The Medical Post. 12 June 2007; 43(21):(center-fold)
    • Diabetes & Periodontal Disease, Canadian Dental Journal, Mar 2008
    • Effects of Ramipril and/or Rosiglitazone on Cardiovascular & Renal Outcomes in People with Impaired Glucose Tolerance or Impaired Fasting Glucose. Diabetes Care. 2008, Vol 30 No 5, May 2008, 1007-1014
    • Clinical Focus: Pharmacologic Management of Type 2 Diabetes. Medical Post, Supplement May 2008
    • A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT Study. DOI: 10.1111/j.1464-5491.2006.01881.x
    • Enhancing Diabetes Care in Family Practice. Can Fam Phys. 54(9), 1237-1238, Sept 2008
    Presentations: (Recent)
    • Insulin Pump Therapy in Young Women: ADA June 2002, San Francisco
    • Community Based Insulin Pump Outcomes: CDA Oct 2002, Vancouver
    • Pioglitazone in Family Practice: CDA Oct 2002, Vancouver
    • Rosiglitazone in Family Practice: CDA Oct 2002, Vancouver
    • Guidelines, Do They Make a Difference: CDA Oct 2002, Vancouver
    • A Community Based Insulin Pump Program: ADA June 2003, New Orleans
    • Application of Rosiglitazone In Clinical Practice: IDF 2003, Paris, France
    • 2003 CDA Clinical Practice Guidelines, are they achievable: CDA 2003, Ottawa
    • Rosiglitazone in Clinical Practice, ADA June 2003
    • Diabetes Flow Sheet. CDA, Oct 2004, Quebec City
    • CPG Guidelines, CDA, Oct 2004, Quebec City, Satellite Symposium
    • Review of Insulin Pump Therapy, NDHN May 05, Cleveland’s House
    • Diabetes Flow Sheet with Feedback to enhance Guideline Compliance. CDA Edmonton 2005
    • Diabetes Flow Sheet with feedback, enhancing diabetes care in family practice, CDA Toronto, Oct 2006
    • Rosiglitazone in Clinical Practice, 6 years experience, International Diabetes Federation, Capetown, Dec 2006
    Continuing Medical Education: (Recent)
    • American Diabetes Assoc, Advanced Postgraduate Course, Jan 2001
    • American Diabetes Assoc. June 2003
    • European Assoc for the study of Diabetes, Budapest Sept 2002
    • Canadian Diabetes Assoc. Oct 2003
    • International Diabetes Federation; Paris Aug 2003
    • American Diabetes Assoc, June 2004
    • Canadian Diabetes Assoc, Canadian Soc of Endocrinology & Metabolism, Oct 2004
    • American Diabetes Assoc Annual Meeting. San Diego June 2005
    • Canadian Diabetes Assoc, Canadian Soc of Endocrinology & Metabolism, Oct 2005
    • American Diabetes Assoc Annual Meeting Washington June 2006
    • European Assoc for the Study of Diabetes, Copenhagen, Sept 2006
    • Canadian Diabetes Assoc, Canadian Soc of Endocrinology & Metabolism, Oct 2006
    • International Diabetes Federation, Capetown, Dec 2006
    • International Diabetes Federation, Capetown, Dec 2006
    • American Diabetes Assoc, Chicago, June 2007
    • European Assoc for the Study of Diabetes, Amsterdam, Sept 2007
    • Canadian Diabetes Assoc, Vancouver, Oct 2007
    • American Diabetes Assoc Annual Meeting, San Francisco, June 2008
    • European Assoc for the Study of Diabetes, Rome, Sept 2008
    • Canadian Diabetes Assoc/CSEM, Montreal Oct 2008
    Other Skills & Personal Interests:
    • Computers in Medicine
    • Associate Editor, Canadian Diabetes
    • Guidelines Dissemination Committee, Canadian Diabetes Assoc
    • Diabetes Advisory Committee, Canadian Pharmacists Association
    • Diabetes Education Web Site www.diabetesclinic.ca
    • Pilot & Aircraft Owner, multi engine, instrument rating, float rating,
    • Helicopter & Fixed Wing Commercial Licenses
    • Ski Patroller, Mont Tremblant, Que
    • Sailing, White Water Kayaking & Canoeing
    • Military Service, Canadian Forces, Capt; Rhodesia Defense Force, Major